According to Galectin Therapeutics's latest financial reports the company's current earnings (TTM) are -$41.07 M. In 2022 the company made an earning of -$38.78 M a decrease over its 2021 earnings that were of -$30.53 M.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$41.07 M | 5.91% |
2022 | -$38.78 M | 27.02% |
2021 | -$30.53 M | 30.1% |
2020 | -$23.47 M | 76.51% |
2019 | -$13.3 M | -4.36% |
2018 | -$13.9 M | -14.38% |
2017 | -$16.24 M | -24.26% |
2016 | -$21.44 M | 7.04% |
2015 | -$20.03 M | 26.85% |
2014 | -$15.79 M | 30.61% |
2013 | -$12.09 M | 27.82% |
2012 | -$9.46 M | -9.15% |
2011 | -$10.41 M | 113.17% |
2010 | -$4.89 M | -19.86% |
2009 | -$6.1 M | 14.4% |
2008 | -$5.33 M | -17.49% |
2007 | -$6.46 M | -8.41% |
2006 | -$7.05 M | 5.91% |
2005 | -$6.66 M | -8.89% |
2004 | -$7.31 M | 47.92% |
2003 | -$4.94 M | 50.22% |
2002 | -$3.29 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Mirati Therapeutics MRTX | -$0.77 B | 1,762.54% | ๐บ๐ธ USA |
MannKind Corp MNKD | -$10.38 M | -74.73% | ๐บ๐ธ USA |